Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17236445 | 0.79 | KDM4E (0.48) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL1253016 | 0.75 | APP (0.47) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL30036439 | 0.74 | MAOB (0.63) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL103158 | 0.74 | MAOB (0.63) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| Hydrochloric Acid SCHEMBL30577224 | 0.73 | KDM4E (0.47) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL1009796 | 0.70 | MAOB (0.48) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL8874655 | 0.70 | KDM4E (0.48) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL276909 | 0.70 | CYP2A6 (0.54) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL21179480 | 0.70 | MAOB (0.48) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL21494529 | 0.70 | KDM4E (0.48) | KDM4ECYP2A6TDP1FLT3LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | claimed |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | claimed |
| EP-2217239-A2 | MODULATION OF PROTEIN TRAFFICKING | Foldrx Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009062118-A2 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | claimed |
| EP-2007373-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | Foldrx Pharmaceuticals, Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007126841-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | claimed |
| US-8592458-B2 | Alpha7 nicotinic receptor selective ligands | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120237563-A1 | CONTROLLED-RELEASE FORMULATIONS OF ANABASEINE COMPOUNDS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2467131-A2 | CONTROLLED-RELEASE FORMULATIONS OF ANABASEINE COMPOUNDS AND USES THEREOF | University of Florida Research Foundation, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120094943-A1 | ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8093269-B2 | Alpha 7 nicotinic receptor selective ligands | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2012-01-10 | — | — | US | disclosed |
| WO-2011022467-A2 | CONTROLLED-RELEASE FORMULATIONS OF ANABASEINE COMPOUNDS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2007126841-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1836182-A2 | HETEROCYCLYLBIPHENYL DERIVATES AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006133303-A1 | ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20060122257-A1 | Phenyl substituted carboxylic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC | 2006-06-08 | — | — | US | disclosed |
| WO-2006055625-A2 | HETEROCYCLYLBIPHENYL DERIVATES AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2005123075-A2 | CONTROLLING ANGIOGENESIS WITH ANABASEINE ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050288333-A1 | Controlling angiogenesis with anabaseine analogs | NATIONAL INSTITUTE OF HEALTH | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094943-A1 | ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS | CHRNA7, CHRNA10, CHRNA5 | KDM4E 3829/4885CYP2A6 2142/4885TDP1 2857/4885 |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | SNCA, PARK7, PINK1 | KDM4E 4683/4885CYP2A6 4531/4885TDP1 356/4885 |
| US-20060122257-A1 | Phenyl substituted carboxylic acids | PTPA, PTPRS, PTPRO | KDM4E 1082/4885CYP2A6 744/4885TDP1 1353/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | KDM4E 4425/4885CYP2A6 4429/4885TDP1 3089/4885 |
| US-20050288333-A1 | Controlling angiogenesis with anabaseine analogs | EDNRB, TEK, FLT4 | KDM4E 2764/4885CYP2A6 4381/4885TDP1 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.